doi:10.1016/j.enzmictec.2010.02.007 Liu C, Hwang C, Liao C (1999) Medium optimization for glutathione production by Saccharomyces cerevisiae
8.0%, HR 0.80, p 27 kg/m) or obese chronic coronary syndrome patients to reduce cardiovascular mortality, MI, or stroke (Class IIa, Level B) [18]
The lower rate of non-CV deaths was because of lower infectious deaths, in particular COVID-19related deaths, suggesting that semaglutide has a favorable outcome in terms of mortality across a broad population of patients with CV disease and obesity ( Besides HbA1c and weight reduction, the criteria for initiating a GLP-1 RA with proven CV benefit should include an estimation of the patient's CV risk
Scand J Gastroenterol 2022
A 2012 meta-analysis published in the Journal of Ethnopharmacology reviewed 14 randomized trials involving berberine supplementation
doi: 10.1002/dmrr.3082 63 MaiorinoMIChiodiniPBellastellaGScappaticcioLLongoMEspositoKet al